Alnylam Pharmaceuticals Joins Max Planck Institute in Legal Action toward Whitehead Institute

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has joined with the Max Planck Society in taking legal action toward the Whitehead Institute for Biomedical Research. Also named in the suit are the Massachusetts Institute of Technology (MIT) and the University of Massachusetts. The complaint, filed in Suffolk County Superior Court in Boston, Massachusetts, alleges that the Whitehead Institute has breached its contractual obligations to Max Planck and Alnylam in the manner in which it is prosecuting the Tuschl I patent applications and in its fiduciary duty to all of the co-owners of the Tuschl I patent series.

Back to news